Upon the completion of this program, attendees should be able to:

• Apply up-to-date guidance on the initiation and use of systemic immunosuppressants and immunomodulators in patients with atopic dermatitis during the COVID-19 pandemic
• Assess the severity of atopic dermatitis and select appropriate treatment options for patients who require intensified therapy
• Review the mechanism of action, efficacy and safety of systemic treatments for atopic dermatitis in pediatric and adult patients

This enduring activity focuses on new developments with biologic therapies when treating moderate-severe AD, shared decision-making between; clinicians, patients, and caregivers, as well as heightened attention to disease burden, including patient quality of life with respect to sleep and social health. A triple-board certified physician in allergy/asthma/immunology, dermatology, and pediatrics reviews the current and emerging treatments for moderate-severe AD as well as best practices for discussing and managing treatments and their side effects with patients over the course of the disease incorporating evidence-based strategies for therapy selection and individualization.

RELEASED DATE: March 11, 2024
EXPIRATION DATE: March 11, 2025

This enduring virtual activity targets healthcare gaps related to the diagnosis, treatment, and individualized management of AD, impacting outcomes through identifying burdens affecting quality of life, assessing disease severity when considering topical vs systemic intervention, and utilizing strategies in shared decision-making when determining guideline-based care.

This enduring virtual activity targets healthcare gaps related to the treatment and management of AD in urban communities, impacting outcomes through identifying determinants that impact health in urban communities, implementing strategies in disease severity assessment across varying skin tones, and guideline-based care.

• Develop treatment regimens that address the immunological and neural components of prurigo nodularis (PN)
• Integrate patient-specific factors, such as quality of life and comorbidities, into the selection of treatment options for the management of PN
• Assess clinical trial data on the efficacy and safety of emerging therapies for the treatment of PN

This enduring TeleECHO educational series focuses on the multiple ways in which patient quality of life is impaired by atopic dermatitis (AD) and the latest evidence on key treatment approaches that may provide timely relief, even in the most complex of cases. Engage with expert discussion to learn more about the benefits of patient-specific treatment strategies and ways to leverage the full range of treatment options, including biologic therapies to improve patient outcomes.

RELEASED DATE: November 27, 2024
EXPIRATION DATE: November 27, 2025

Wednesday, February 19, 2025

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM Central, 11:00AM Mountain and 10:00AM Pacific.

Wednesday, February 12, 2025

12:00PM – 1:00PM ET

Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.

Monday, February 3, 2025

12:00PM – 1:00PM ET

Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.